Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1256)
  2. Journal Article (1061)
  3. Review (108)
  4. Editorial (54)
  5. Research Letter (31)
  6. Book Section (22)
  7. Correspondence (20)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (2470)
  2. Solid Tumor Oncology Division (1885)
  3. Hematologic Malignancies, Division of (1191)
  4. GSK Faculty (1125)
  5. Department of Pathology and Laboratory Medicine (917)
  6. Epidemiology and Biostatistics (863)

More Groups

People
  1. Michael Berger (215)
  2. Marc Ladanyi (191)
  3. Pedram Razavi (184)
  4. Michael Offin (173)
  5. David Solit (166)
  6. Maria Carlo (166)

More People

Years
  1. 2025 (152)
  2. 2024 (370)
  3. 2023 (292)
  4. 2022 (347)
  5. 2021 (307)
  6. 2020 (307)

More Years

Publications
  1. Journal of Clinical Oncology (547)
  2. Blood (248)
  3. Annals of Oncology (98)
  4. Clinical Cancer Research (95)
  5. Journal of Thoracic Oncology (82)
  6. Cancer Research (80)

More Publications

Publishers
  1. American Society of Clinical Oncology (618)
  2. Elsevier Inc. (355)
  3. American Society of Hematology (282)
  4. American Association for Cancer Research (217)
  5. Nature Publishing Group (177)
  6. Oxford University Press (147)

More Publishers

Results (2567)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer
    Meeting Abstract

    Desilets, A.; Pfister, D. G.; Wong, W.; Sherman, E. J.; Fetten, J. V.; Hung, K. W.; Dunn, L.; Ho, A. L.; Michel, L. S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Meeting Abstract

    Mohamadpour, M.; Sherman, E. J.; Kriplani, A.; Fetten, J. V.; Dunn, L.; Michel, L. S.; Hung, K. W.; Baxi, S. S.; McDonald, E.; Conybeare, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Chung, C. H.; Colevas, A. D. D.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Burtness, B.; Johnson, F. M.; Julian, R. A.; Saba, N. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Wong, W.; Cracchiolo, J. R.; Riaz, N.; Ganly, I.; Sherman, E. J.; Ho, A. L.; Morris, L.; Ghossein, R. A.; Haque, S.; Hung, K. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Guercio, B. J.; Ratna, N.; Gavrilov, D.; Duzgol, C.; Akhlaq, M.; Teo, M. Y.; Regazzi, A. M.; Kotecha, R. R.; Funt, S. A.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT)
    Meeting Abstract

    Funt, S. A.; Knezevic, A.; Freeman, B. A.; Bolos, M.; Martorana, V.; Donoghue, M.; Khan, S.; Singh, H.; Bromberg, M.; Quinlan, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types
    Meeting Abstract

    Carlo, M. I.; Schroeder, A.; Mukherjee, S.; Kemel, Y.; Kotecha, R. R.; Lee, C. H.; Shah, N. J.; Feldman, D. R.; Liu, Y. L.; Walsh, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
    Meeting Abstract

    Fitzgerald, K. N.; Kotecha, R. R.; Knezevic, A.; Shapnik, N.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save